Patents by Inventor Prakash Jagtap

Prakash Jagtap has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ATP-REGULATED POTASSIUM CHANNEL OPENERS AND USES THEREOF
    Publication number: 20220324809
    Abstract: Compounds and compositions including an ATP-regulated potassium (KATP) channel opener can be including in pharmaceutical compositions. These compounds and compositions are useful for prevention, treatment, or management of pulmonary arterial or venous hypertension. The composition including the compounds may be formulated for intravenous, intraarterial, intramuscular, intranasal, rectal, anal, intravaginal, intratracheal, intraperitoneal, or subcutaneous, administration, or for inhalation.
    Type: Application
    Filed: September 2, 2020
    Publication date: October 13, 2022
    Inventors: Prakash JAGTAP, Andrew Lurie SALZMAN
  • CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF
    Publication number: 20210009549
    Abstract: Cannavinoid derivatives, such as cannabidiol (CBD), desoxy-CBD, and desoxy-?9-tetrahydrocannabinol (desoxy-THC) derivatives, or an enantiomer, diastereomer, racemate, or pharmaceutically acceptable salt thereof, are useful for neuroprotection, treating pain, or treating a disease associated with alpha-1 glycine receptor (?1GlyR) and/or alpha-3 glycine receptor (?3GlyR) deficiency. Drug conjugates of the derivatives can be made.
    Type: Application
    Filed: February 13, 2019
    Publication date: January 14, 2021
    Inventors: Prakash JAGTAP, Dana SHOKEN, Shlomit AVIDAN- SHLOMOVICH, Andrew Lurie SALZMAN
  • METHODS FOR TOTAL SYNTHESIS OF RESOLVIN E1
    Publication number: 20180297925
    Abstract: Methods for total chemical synthesis of Resolvin E1 (RvE1) include Wittig reaction of two compounds having hydroxyl protecting group in the presence of a strong base, removal of the hydroxyl-protecting groups with a deprotecting reagent to produce a compound having an ester group, and hydrolysis of the ester group to obtain RvE1
    Type: Application
    Filed: October 9, 2016
    Publication date: October 18, 2018
    Inventor: Prakash Jagtap
  • Method for treating diseases associated with oxidative stress or endothelial dysfunction using substituted 1-pyrrolidinyloxy, 1-piperidinyloxy and 1-azepanyloxy compounds
    Patent number: 10000455
    Abstract: A method reduces oxidative stress or endothelial dysfunction in a mammal. The method includes administering to the mammal a compound of formula I: or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt of the compound.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: June 19, 2018
    Assignee: Salzman Group, Inc.
    Inventors: Andrew Lurie Salzman, Prakash Jagtap, Garry John Southan
  • METHOD FOR TREATING DISEASES ASSOCIATED WITH OXIDATIVE STRESS OR ENDOTHELIAL DYSFUNCTION
    Publication number: 20170327466
    Abstract: A method reduces oxidative stress or endothelial dysfunction in a mammal. The method includes administering to the mammal a compound of formula I: or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt of the compound.
    Type: Application
    Filed: March 27, 2017
    Publication date: November 16, 2017
    Inventors: Andrew Lurie Salzman, Prakash Jagtap, Garry John Southan
  • MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF
    Publication number: 20170107198
    Abstract: Multifunctional nitroxide derivatives contain a potassium channel opener and a reactive oxygen species (ROS) degradation catalyst that can act as an anti-oxidant. Pharmaceutical compositions can include the derivatives. The multifunctional compounds and pharmaceutical compositions are useful for treatment of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 20, 2017
    Inventors: Prakash Jagtap, Andrew Lurie Salzman
  • COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG
    Publication number: 20170095445
    Abstract: Methods are for treatment of an inflammatory disease of the lung caused by inhalation of a toxic agent or an irritant, such as chlorine inhalational lung injury. The methods include administration of compositions including certain compounds.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 6, 2017
    Inventors: Andrew Lurie Salzman, Prakash Jagtap, Garry John Southan
  • Substituted 1-pyrrolidinyloxy, 1-piperidinyloxy and 1-azepanyloxy compounds for treating diseases associated with oxidative stress or endothelial dysfunction
    Patent number: 9604932
    Abstract: Compounds are of the class of 1-pyrrolidinyloxy,1-piperidinyloxy, and 1-azepanyloxy derivatives of formula (I): The compounds are useful in prevention, treatment or management of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction. The compounds include 2,2,5,5,-tetramethyl-3-(nitrooxymethyl)pyrrolidin-1-yl acetate.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: March 28, 2017
    Assignee: Radikal Therapeutics Inc.
    Inventors: Andrew Lurie Salzman, Prakash Jagtap, Garry John Southan
  • Use of small molecule inhibitors targeting the interaction between RAC GTPase and p67
    Patent number: 9567347
    Abstract: Inhibitors of p67phox protein are provided herein, as well as pharmaceutical compositions and methods relating thereto.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: February 14, 2017
    Assignee: Children's Hospital Medical Center
    Inventors: Yi Zheng, Prakash Jagtap, Emily E. Bosco, Jaroslaw Meller, Marie-Dominique Filippi
  • Multifunctional nitroxide derivatives and uses thereof
    Patent number: 9522903
    Abstract: Multifunctional nitroxide derivatives comprising a potassium channel opener and a reactive oxygen species (ROS) degradation catalyst that can act as an anti-oxidant, as well as pharmaceutical compositions comprising them are provided. The multifunctional compounds and pharmaceutical compositions are useful for treatment of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: December 20, 2016
    Assignee: Radikal Therapeutics Inc.
    Inventors: Prakash Jagtap, Andrew Lurie Salzman
  • USE OF SMALL MOLECULE INHIBITORS TARGETING THE INTERACTION BETWEEN RAC GTPASE AND P67(PHOX)
    Publication number: 20160297835
    Abstract: Inhibitors of p67phox protein are provided herein, as well as pharmaceutical compositions and methods relating thereto.
    Type: Application
    Filed: April 8, 2016
    Publication date: October 13, 2016
    Inventors: Yi Zheng, Prakash Jagtap, Emily E. Bosco, Jaroslaw Meller, Marie-Dominique Filippi
  • Use of small molecule inhibitors targeting the interaction between Rac GTPase and p67 (phox)
    Patent number: 9453022
    Abstract: Inhibitors of p67phox protein are provided herein, as well as pharmaceutical compositions and methods recited thereto.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: September 27, 2016
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Yi Zheng, Prakash Jagtap, Emily E. Bosco, Jaroslaw Meller, Marie-Dominique Filippi
  • METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS
    Publication number: 20160158268
    Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Application
    Filed: February 16, 2016
    Publication date: June 9, 2016
    Inventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Prakash JAGTAP
  • Use of small molecule inhibitors targeting the interaction between Rac GTPase and p67 (phox)
    Patent number: 9334284
    Abstract: Inhibitors of p67phox protein are provided herein, as well as pharmaceutical compositions and methods recited thereto.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: May 10, 2016
    Assignee: Children's Hospital Medical Center
    Inventors: Yi Zheng, Prakash Jagtap, Emily E. Bosco, Jaroslaw Meller, Marie-Dominique Filippi
  • Method of reducing intraocular pressure in humans
    Patent number: 9289383
    Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: March 22, 2016
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Prakash Jagtap
  • PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF
    Publication number: 20160002171
    Abstract: Prodrugs of compounds comprise a nitric oxide donor and a reactive oxygen species (ROS) degradation catalyst, in particular, 1-pyrrolidinyloxy, 1-piperidinyloxy, and 1-azepanyloxy derivatives, and pharmaceutical compositions thereof. These compounds and pharmaceutical compositions are useful in prevention, treatment or management of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction.
    Type: Application
    Filed: March 5, 2013
    Publication date: January 7, 2016
    Inventors: Andrew Lurie Salzman, Prakash Jagtap, Garry John Southan
  • COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG
    Publication number: 20150368197
    Abstract: Pharmaceutical compositions and methods are for treatment of an inflammatory disease of the lung caused by inhalation of a toxic agent or an irritant. In one example, chlorine inhalational lung injury can be treated using compounds useful in such compositions.
    Type: Application
    Filed: June 20, 2013
    Publication date: December 24, 2015
    Inventors: Andrew Lurie Salzman, Prakash Jagtap, Garry John Southan
  • MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF
    Publication number: 20150336932
    Abstract: Multifunctional nitroxide derivatives comprising a potassium channel opener and a reactive oxygen species (ROS) degradation catalyst that can act as an anti-oxidant, as well as pharmaceutical compositions comprising them are provided. The multifunctional compounds and pharmaceutical compositions are useful for treatment of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 26, 2015
    Inventors: Prakash Jagtap, Andrew Lurie Salzman
  • Multifunctional nitroxide derivatives and uses thereof
    Patent number: 9102659
    Abstract: Multifunctional nitroxide derivatives comprising a potassium channel opener and a reactive oxygen species (ROS) degradation catalyst that can act as an anti-oxidant, as well as pharmaceutical compositions comprising them are provided. The multifunctional compounds and pharmaceutical compositions are useful for treatment of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: August 11, 2015
    Assignee: RADIKAL THERAPEUTICS INC.
    Inventors: Prakash Jagtap, Andrew Lurie Salzman
  • METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS
    Publication number: 20150080330
    Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Inventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Prakash JAGTAP